CoChat
Sign Up
Cited by 153

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines

Stephens, Alexander J., Burgess-Brown, Nicola A., Jiang, Shisong·2021·Frontiers in Immunology
DOI 10.3389/fimmu.2021.696791
Open this paper in CoChat — free account

Abstract

Peptide-based cancer vaccines rely upon the strong activation of the adaptive immune response to elicit its effector function. They have shown to be highly specific and safe, but have yet to prove themselves as an efficacious treatment for cancer in the clinic. This is for a variety of reasons, including tumour heterogeneity, self-tolerance, and immune suppression. Importance has been placed on the overall design of peptide-based cancer vaccines, which have evolved from simple peptide derivatives of a cancer antigen, to complex drugs; incorporating overlapping regions, conjugates, and delivery systems to target and stimulate different components of antigen presenting cells, and to bolster antigen cross-presentation. Peptide-based cancer vaccines are increasingly becoming more personalised to an individual’s tumour antigen repertoire and are often combined with existing cancer treatments. This strategy ultimately aids in combating the shortcomings of a more generalised vaccine strategy and provides a comprehensive treatment, taking into consideration cancer cell variability and its ability to avoid immune interrogation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2021.696791

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 7 references

Research works printed but not linked: 125

  1. Clem, 2011, Fundamentals of Vaccine Immunology, J Glob Infect Dis, 3, 10.4103/0974-777X.77299 · DOI
  2. Hanahan, 2011, Hallmarks of Cancer: The Next Generation, Cell, 144, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  3. Mittal, 2014, New Insights Into Cancer Immunoediting and Its Three Component Phases–Elimination, Equilibrium and Escape, Curr Opin Immunol, 27, 16, 10.1016/j.coi.2014.01.004 · DOI · Paper page
  4. Whiteside, 2008, The Tumor Microenvironment and Its Role in Promoting Tumor Growth, Oncogene, 27, 10.1038/onc.2008.271 · DOI · Paper page
  5. Balkwill, 2012, The Tumor Microenvironment at a Glance, J Cell Sci, 125, 10.1242/jcs.116392 · DOI · Paper page
  6. Gillet, 2010, Mechanisms of Multidrug Resistance in Cancer, Methods Mol Biol, 596, 47, 10.1007/978-1-60761-416-6_4 · DOI
  7. Mansoori, 2017, The Different Mechanisms of Cancer Drug Resistance: A Brief Review, Adv Pharm Bull, 7, 10.15171/apb.2017.041 · DOI
  8. Steinman, 2006, Linking Innate to Adaptive Immunity Through Dendritic Cells, Novartis Found Symp, 279, 10.1002/9780470035399.ch9 · DOI
  9. Mosmann, 1989, TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties, Annu Rev Immunol, 7, 10.1146/annurev.iy.07.040189.001045 · DOI · Paper page
  10. Bonnerot, 1997, Intracellular Signaling and Endosomal Trafficking of Immunoreceptors. Shared Effectors Underlying MHC Class II-Restricted Antigen Presentation, Immunol Lett, 57, 1, 10.1016/S0165-2478(97)00054-0 · DOI
  11. Schroder, 2004, Interferon-Gamma: An Overview of Signals, Mechanisms and Functions, J Leukoc Biol, 75, 10.1189/jlb.0603252 · DOI · Paper page
  12. Joffre, 2012, Cross-Presentation by Dendritic Cells, Nat Rev Immunol, 12, 10.1038/nri3254 · DOI
  13. Halle, 2017, Mechanisms and Dynamics of T Cell-Mediated Cytotoxicity In Vivo, Trends Immunol, 38, 10.1016/j.it.2017.04.002 · DOI · Paper page
  14. Janeway, 1992, The T Cell Receptor as a Multicomponent Signalling Machine: CD4/CD8 Coreceptors and CD45 in T Cell Activation, Annu Rev Immunol, 10, 10.1146/annurev.iy.10.040192.003241 · DOI
  15. Daniels, 2000, Critical Role for CD8 in T Cell Receptor Binding and Activation by Peptide/Major Histocompatibility Complex Multimers, J Exp Med, 191, 10.1084/jem.191.2.335 · DOI
  16. Artyomov, 2010, CD4 and CD8 Binding to MHC Molecules Primarily Acts to Enhance Lck Delivery, Proc Natl Acad Sci USA, 107, 10.1073/pnas.1010568107 · DOI · Paper page
  17. McAdam, 1998, The Role of B7 Co-Stimulation in Activation and Differentiation of CD4+ and CD8+ T Cells, Immunol Rev, 165, 10.1111/j.1600-065X.1998.tb01242.x · DOI
  18. Heufler, 1996, Interleukin-12 is Produced by Dendritic Cells and Mediates T Helper 1 Development as Well as Interferon-Gamma Production by T Helper 1 Cells, Eur J Immunol, 26, 10.1002/eji.1830260323 · DOI
  19. Curtsinger, 2010, Inflammatory Cytokines as a Third Signal for T Cell Activation, Curr Opin Immunol, 22, 10.1016/j.coi.2010.02.013 · DOI
  20. Keppler, 2012, Signal 3 Cytokines as Modulators of Primary Immune Responses During Infections: The Interplay of Type I IFN and IL-12 in CD8 T Cell Responses, PLoS One, 7, e40865, 10.1371/journal.pone.0040865 · DOI
  21. Hatziioannou, 2017, Myeloid-Derived Suppressor Cells and T Regulatory Cells in Tumors: Unraveling the Dark Side of the Force, J Leukoc Biol, 102, 10.1189/jlb.5VMR1116-493R · DOI
  22. Tay, 2020, Revisiting the Role of CD4(+) T Cells in Cancer Immunotherapy-New Insights Into Old Paradigms, Cancer Gene Ther, 28, 5, 10.1038/s41417-020-0183-x · DOI
  23. Bijker, 2008, Superior Induction of Anti-Tumor CTL Immunity by Extended Peptide Vaccines Involves Prolonged, DC-Focused Antigen Presentation, Eur J Immunol, 38, 10.1002/eji.200737995 · DOI
  24. Sidney, 1995, Several HLA Alleles Share Overlapping Peptide Specificities, J Immunol, 154, 10.4049/jimmunol.154.1.247 · DOI
  25. Southwood, 1998, Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires, J Immunol, 160, 10.4049/jimmunol.160.7.3363 · DOI
  26. Diao, 2013, Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Correlations of Therapeutic Peptides, Clin Pharmacokinet, 52, 10.1007/s40262-013-0079-0 · DOI
  27. Di, 2015, Strategic Approaches to Optimizing Peptide ADME Properties, AAPS J, 17, 10.1208/s12248-014-9687-3 · DOI · Paper page
  28. Khong, 2016, Adjuvants for Peptide-Based Cancer Vaccines, J Immunother Cancer, 4, 56, 10.1186/s40425-016-0160-y · DOI
  29. Gouttefangeas, 2018, Personalized Cancer Vaccines: Adjuvants are Important, Too, Cancer Immunol Immunother, 67, 10.1007/s00262-018-2158-4 · DOI
  30. Marincola, 2000, Escape of Human Solid Tumors From T-Cell Recognition: Molecular Mechanisms and Functional Significance, Adv Immunol, 74, 181, 10.1016/S0065-2776(08)60911-6 · DOI
  31. McGranahan, 2017, Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future, Cell, 168, 10.1016/j.cell.2017.01.018 · DOI · Paper page
  32. Han, 2019, Regulation of the Translation Activity of Antigen-Specific mRNA Is Responsible for Antigen Loss and Tumor Immune Escape in a HER2-Expressing Tumor Model, Sci Rep, 9, 2855, 10.1038/s41598-019-39557-9 · DOI
  33. Romero, 2012, The Tumour Suppressor Fhit Positively Regulates MHC Class I Expression on Cancer Cells, J Pathol, 227, 10.1002/path.4029 · DOI
  34. Morrison, 2018, Reduction of MHC-I Expression Limits T-Lymphocyte-Mediated Killing of Cancer-Initiating Cells, BMC Cancer, 18, 469, 10.1186/s12885-018-4389-3 · DOI
  35. Melero, 2014, T-Cell and NK-Cell Infiltration Into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy, Cancer Discov, 4, 10.1158/2159-8290.CD-13-0985 · DOI
  36. Betts, 2012, Suppression of Tumour-Specific CD4(+) T Cells by Regulatory T Cells is Associated With Progression of Human Colorectal Cancer, Gut, 61, 10.1136/gutjnl-2011-300970 · DOI
  37. Xia, 2019, T Cell Dysfunction in Cancer Immunity and Immunotherapy, Front Immunol, 10, 10.3389/fimmu.2019.01719 · DOI
  38. Walters, 2017, A Novel DNA Vaccine Platform Enhances Neo-Antigen-Like T Cell Responses Against WT1 to Break Tolerance and Induce Anti-Tumor Immunity, Mol Ther, 25, 10.1016/j.ymthe.2017.01.022 · DOI
  39. Flingai, 2013, Synthetic DNA Vaccines: Improved Vaccine Potency by Electroporation and Co-Delivered Genetic Adjuvants, Front Immunol, 4, 10.3389/fimmu.2013.00354 · DOI
  40. Hobernik, 2018, DNA Vaccines-How Far From Clinical Use, Int J Mol Sci, 19, 3605, 10.3390/ijms19113605 · DOI
  41. Dupuis, 2000, Distribution of DNA Vaccines Determines Their Immunogenicity After Intramuscular Injection in Mice, J Immunol, 165, 10.4049/jimmunol.165.5.2850 · DOI · Paper page
  42. Miao, 2021, mRNA Vaccine for Cancer Immunotherapy, Mol Cancer, 20, 41, 10.1186/s12943-021-01335-5 · DOI
  43. Rosenberg, 2015, Adoptive Cell Transfer as Personalized Immunotherapy for Human Cancer, Science, 348, 10.1126/science.aaa4967 · DOI
  44. Hay, 2019, CAR T-Cells: Costs, Comparisons, and Commentary, J Med Econ, 22, 10.1080/13696998.2019.1582059 · DOI
  45. Rosenberg, 2008, Adoptive Cell Transfer: A Clinical Path to Effective Cancer Immunotherapy, Nat Rev Cancer, 8, 299, 10.1038/nrc2355 · DOI
  46. Brudno, 2016, Toxicities of Chimeric Antigen Receptor T Cells: Recognition and Management, Blood, 127, 10.1182/blood-2016-04-703751 · DOI · Paper page
  47. Wilgenhof, 2013, A Phase IB Study on Intravenous Synthetic mRNA Electroporated Dendritic Cell Immunotherapy in Pretreated Advanced Melanoma Patients, Ann Oncol, 24, 10.1093/annonc/mdt245 · DOI
  48. Yoshida, 2011, Characteristics of Severe Adverse Events After Peptide Vaccination for Advanced Cancer Patients: Analysis of 500 Cases, Oncol Rep, 25, 57, 10.3892/or_00001041 · DOI
  49. Sanchez-Trincado, 2017, Fundamentals and Methods for T- and B-Cell Epitope Prediction, J Immunol Res, 2017, 2680160, 10.1155/2017/2680160 · DOI
  50. Lehmann, 2019, Comprehensive Evaluation of the Expressed CD8+ T Cell Epitope Space Using High-Throughput Epitope Mapping, Front Immunol, 10, 10.3389/fimmu.2019.00655 · DOI
  51. Ahmad, 2016, T-Cell Epitope Mapping for the Design of Powerful Vaccines, Vaccine Rep, 6, 13, 10.1016/j.vacrep.2016.07.002 · DOI
  52. Zwaveling, 2002, Established Human Papillomavirus Type 16-Expressing Tumors are Effectively Eradicated Following Vaccination With Long Peptides, J Immunol, 169, 10.4049/jimmunol.169.1.350 · DOI
  53. Speetjens, 2009, Induction of P53-Specific Immunity by a P53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer, Clin Cancer Res, 15, 10.1158/1078-0432.CCR-08-2227 · DOI · Paper page
  54. van Poelgeest, 2013, HPV16 Synthetic Long Peptide (HPV16-SLP) Vaccination Therapy of Patients With Advanced or Recurrent HPV16-Induced Gynecological Carcinoma, a Phase II Trial, J Transl Med, 11, 88, 10.1186/1479-5876-11-88 · DOI
  55. Rosalia, 2013, Dendritic Cells Process Synthetic Long Peptides Better Than Whole Protein, Improving Antigen Presentation and T-Cell Activation, Eur J Immunol, 43, 10.1002/eji.201343324 · DOI
  56. Melief, 2008, Immunotherapy of Established (Pre)Malignant Disease by Synthetic Long Peptide Vaccines, Nat Rev Cancer, 8, 10.1038/nrc2373 · DOI · Paper page
  57. Slingluff, 2011, The Present and Future of Peptide Vaccines for Cancer: Single or Multiple, Long or Short, Alone or in Combination, Cancer J, 17, 10.1097/PPO.0b013e318233e5b2 · DOI
  58. Rabu, 2019, Cancer Vaccines: Designing Artificial Synthetic Long Peptides to Improve Presentation of Class I and Class II T Cell Epitopes by Dendritic Cells, Oncoimmunology, 8, e1560919, 10.1080/2162402X.2018.1560919 · DOI
  59. Shen, 2004, Important Role of Cathepsin S in Generating Peptides for TAP-Independent MHC Class I Crosspresentation In Vivo, Immunity, 21, 10.1016/j.immuni.2004.07.004 · DOI
  60. Riese, 2000, Cathepsins and Compartmentalization in Antigen Presentation, Curr Opin Immunol, 12, 10.1016/S0952-7915(99)00058-8 · DOI
  61. Schmidt, 2003, Survivin Is a Shared Tumor-Associated Antigen Expressed in a Broad Variety of Malignancies and Recognized by Specific Cytotoxic T Cells, Blood, 102, 10.1182/blood-2002-08-2554 · DOI
  62. Onodi, 2018, High Therapeutic Efficacy of a New Survivin LSP-Cancer Vaccine Containing CD4(+) and CD8(+) T-Cell Epitopes, Front Oncol, 8, 10.3389/fonc.2018.00517 · DOI
  63. Ambrosini, 1997, A Novel Anti-Apoptosis Gene, Survivin, Expressed in Cancer and Lymphoma, Nat Med, 3, 10.1038/nm0897-917 · DOI
  64. Ciesielski, 2010, Antitumor Cytotoxic T-Cell Response Induced by a Survivin Peptide Mimic, Cancer Immunol Immunother, 59, 10.1007/s00262-010-0845-x · DOI
  65. Zhang, 2009, Comparing Pooled Peptides With Intact Protein for Accessing Cross-Presentation Pathways for Protective CD8+ and CD4+ T Cells, J Biol Chem, 284, 10.1074/jbc.M809456200 · DOI
  66. Cai, 2017, Protective Cellular Immunity Generated by Cross-Presenting Recombinant Overlapping Peptide Proteins, Oncotarget, 8, 10.18632/oncotarget.20407 · DOI
  67. Greenbaum, 2011, Functional Classification of Class II Human Leukocyte Antigen (HLA) Molecules Reveals Seven Different Supertypes and a Surprising Degree of Repertoire Sharing Across Supertypes, Immunogenetics, 63, 10.1007/s00251-011-0513-0 · DOI
  68. Nielsen, 2010, MHC Class II Epitope Predictive Algorithms, Immunology, 130, 10.1111/j.1365-2567.2010.03268.x · DOI
  69. Hilf, 2019, Actively Personalized Vaccination Trial for Newly Diagnosed Glioblastoma, Nature, 565, 10.1038/s41586-018-0810-y · DOI · Paper page
  70. Stupp, 2005, Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma, N Engl J Med, 352, 10.1056/NEJMoa043330 · DOI · Paper page
  71. Blass, 2021, Advances in the Development of Personalized Neoantigen-Based Therapeutic Cancer Vaccines, Nat Rev Clin Oncol, 18, 215, 10.1038/s41571-020-00460-2 · DOI · Paper page
  72. Fang, 2014, TLR4 is Essential for Dendritic Cell Activation and Anti-Tumor T-Cell Response Enhancement by DAMPs Released From Chemically Stressed Cancer Cells, Cell Mol Immunol, 11, 10.1038/cmi.2013.59 · DOI
  73. Dalod, 2014, Dendritic Cell Maturation: Functional Specialization Through Signaling Specificity and Transcriptional Programming, EMBO J, 33, 10.1002/embj.201488027 · DOI
  74. Oth, 2016, Pathogen-Associated Molecular Patterns Induced Crosstalk Between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination, Mediators Inflamm, 2016, 5740373, 10.1155/2016/5740373 · DOI
  75. Oth, 2015, Potency of Both Human Th1 and NK Helper Cell Activation is Determined by IL-12p70-Producing PAMP-Matured DCs, J Interferon Cytokine Res, 35, 10.1089/jir.2015.0022 · DOI
  76. Yang, 2019, Prevention and Treatment of Cervical Cancer by a Single Administration of Human Papillomavirus Peptide Vaccine With CpG Oligodeoxynucleotides as an Adjuvant In Vivo, Int Immunopharmacol, 69, 10.1016/j.intimp.2019.01.024 · DOI
  77. Willems, 2014, N-Tetradecylcarbamyl Lipopeptides as Novel Agonists for Toll-Like Receptor 2, J Med Chem, 57, 10.1021/jm500722p · DOI
  78. Zom, 2018, Novel TLR2-Binding Adjuvant Induces Enhanced T Cell Responses and Tumor Eradication, J Immunother Cancer, 6, 146, 10.1186/s40425-018-0455-2 · DOI
  79. Zom, 2016, TLR2 Ligand-Synthetic Long Peptide Conjugates Effectively Stimulate Tumor-Draining Lymph Node T Cells of Cervical Cancer Patients, Oncotarget, 7, 10.18632/oncotarget.11512 · DOI
  80. Macri, 2016, Targeting Dendritic Cells: A Promising Strategy to Improve Vaccine Effectiveness, Clin Transl Immunol, 5, e66, 10.1038/cti.2016.6 · DOI
  81. Shrimpton, 2009, CD205 (DEC-205): A Recognition Receptor for Apoptotic and Necrotic Self, Mol Immunol, 46, 10.1016/j.molimm.2008.11.016 · DOI
  82. Lahoud, 2012, DEC-205 is a Cell Surface Receptor for CpG Oligonucleotides, Proc Natl Acad Sci U S A, 109, 10.1073/pnas.1208796109 · DOI
  83. Liu, 2016, A Novel Dendritic Cell Targeting HPV16 E7 Synthetic Vaccine in Combination With PD-L1 Blockade Elicits Therapeutic Antitumor Immunity in Mice, Oncoimmunology, 5, e1147641, 10.1080/2162402X.2016.1147641 · DOI
  84. Dorner, 2009, Selective Expression of the Chemokine Receptor XCR1 on Cross-Presenting Dendritic Cells Determines Cooperation With CD8+ T Cells, Immunity, 31, 10.1016/j.immuni.2009.08.027 · DOI
  85. Kroczek, 2012, The Role of XCR1 and its Ligand XCL1 in Antigen Cross-Presentation by Murine and Human Dendritic Cells, Front Immunol, 3, 10.3389/fimmu.2012.00014 · DOI
  86. Botelho, 2019, Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control, Front Immunol, 10, 10.3389/fimmu.2019.00294 · DOI
  87. Belnoue, 2019, Targeting Self and Neo-Epitopes With a Modular Self-Adjuvanting Cancer Vaccine, JCI Insight, 5, e127305, 10.1172/jci.insight.127305 · DOI
  88. Wu, 2019, Cell-Penetrating Peptide Enhanced Antigen Presentation for Cancer Immunotherapy, Bioconjug Chem, 30, 10.1021/acs.bioconjchem.9b00245 · DOI
  89. Zahid, 2015, Cell-Type Specific Penetrating Peptides: Therapeutic Promises and Challenges, Molecules, 20, 10.3390/molecules200713055 · DOI
  90. Wang, 2014, Mannose Derivative and Lipid A Dually Decorated Cationic Liposomes as an Effective Cold Chain Free Oral Mucosal Vaccine Adjuvant-Delivery System, Eur J Pharm Biopharm, 88, 194, 10.1016/j.ejpb.2014.04.007 · DOI
  91. De Serrano, 2017, Liposomal Vaccine Formulations as Prophylactic Agents: Design Considerations for Modern Vaccines, J Nanobiotechnol, 15, 83, 10.1186/s12951-017-0319-9 · DOI
  92. Stark, 2008, Liposomal Vasoactive Intestinal Peptide for Lung Application: Protection From Proteolytic Degradation, Eur J Pharm Biopharm, 70, 10.1016/j.ejpb.2008.04.015 · DOI
  93. Arbelaez, 2020, A Nanoparticle Vaccine That Targets Neoantigen Peptides to Lymphoid Tissues Elicits Robust Antitumor T Cell Responses, NPJ Vaccines, 5, 106, 10.1038/s41541-020-00253-9 · DOI
  94. Chatin, 2015, Liposome-Based Formulation for Intracellular Delivery of Functional Proteins, Mol Ther Nucleic Acids, 4, e244, 10.1038/mtna.2015.17 · DOI
  95. Rueda, 2017, Effect of TLR Ligands Co-Encapsulated With Multiepitopic Antigen in Nanoliposomes Targeted to Human DCs via Fc Receptor for Cancer Vaccines, Immunobiology, 222, 10.1016/j.imbio.2017.06.002 · DOI
  96. Zamani, 2019, MPL Nano-Liposomal Vaccine Containing P5 HER2/neu-Derived Peptide Pulsed PADRE as an Effective Vaccine in a Mice TUBO Model of Breast Cancer, J Control Release, 303, 10.1016/j.jconrel.2019.04.019 · DOI
  97. Alexander, 1994, Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides, Immunity, 1, 10.1016/S1074-7613(94)80017-0 · DOI
  98. Du, 2014, The Role of the Helper Lipid on the DNA Transfection Efficiency of Lipopolyplex Formulations, Sci Rep, 4, 7107, 10.1038/srep07107 · DOI
  99. Zamani, 2020, Nanoliposomal Vaccine Containing Long Multi-Epitope Peptide E75-AE36 Pulsed PADRE-Induced Effective Immune Response in Mice TUBO Model of Breast Cancer, Eur J Cancer, 129, 80, 10.1016/j.ejca.2020.01.010 · DOI
  100. Varypataki, 2016, Synthetic Long Peptide-Based Vaccine Formulations for Induction of Cell Mediated Immunity: A Comparative Study of Cationic Liposomes and PLGA Nanoparticles, J Control Release, 226, 98, 10.1016/j.jconrel.2016.02.018 · DOI
  101. Jacoberger-Foissac, 2019, Optimization of Peptide-Based Cancer Vaccine Compositions, by Sequential Screening, Using Versatile Liposomal Platform, Int J Pharm, 562, 10.1016/j.ijpharm.2019.03.002 · DOI
  102. Khong, 2018, Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8(+) T Cell Response, J Immunol, 200, 10.4049/jimmunol.1700467 · DOI
  103. Kordalivand, 2019, Cationic Synthetic Long Peptides-Loaded Nanogels: An Efficient Therapeutic Vaccine Formulation for Induction of T-Cell Responses, J Control Release, 315, 10.1016/j.jconrel.2019.10.048 · DOI
  104. Wei, 2019, Smart pH-Sensitive Nanogels for Controlled Release in an Acidic Environment, Biomacromolecules, 20, 10.1021/acs.biomac.8b01228 · DOI
  105. Klinger, 2012, Enzymatically Degradable Nanogels by Inverse Miniemulsion Copolymerization of Acrylamide With Dextran Methacrylates as Crosslinkers, Polymer Chem, 3, 10.1039/C1PY00415H · DOI
  106. Lynn, 2020, Peptide-TLR-7/8a Conjugate Vaccines Chemically Programmed for Nanoparticle Self-Assembly Enhance CD8 T-Cell Immunity to Tumor Antigens, Nat Biotechnol, 38, 10.1038/s41587-019-0390-x · DOI
  107. Chikuma, 2016, Basics of PD-1 in Self-Tolerance, Infection, and Cancer Immunity, Int J Clin Oncol, 21, 10.1007/s10147-016-0958-0 · DOI
  108. Topalian, 2015, Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy, Cancer Cell, 27, 10.1016/j.ccell.2015.03.001 · DOI · Paper page
  109. Petricevic, 2013, Trastuzumab Mediates Antibody-Dependent Cell-Mediated Cytotoxicity and Phagocytosis to the Same Extent in Both Adjuvant and Metastatic HER2/neu Breast Cancer Patients, J Transl Med, 11, 307, 10.1186/1479-5876-11-307 · DOI
  110. Gall, 2017, Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells, Cancer Res, 77, 10.1158/0008-5472.CAN-16-2774 · DOI
  111. Hickerson, 2019, Final Analysis of Nelipepimut-S Plus GM-CSF With Trastuzumab Versus Trastuzumab Alone to Prevent Recurrences in High-Risk, HER2 Low-Expressing Breast Cancer: A Prospective, Randomized, Blinded, Multicenter Phase IIb Trial, J Clin Oncol, 37, 1, 10.1200/JCO.2019.37.8_suppl.1 · DOI
  112. Noguchi, 2020, Mixed 20-Peptide Cancer Vaccine in Combination With Docetaxel and Dexamethasone for Castration-Resistant Prostate Cancer: A Randomized Phase II Trial, Cancer Immunol Immunother, 69, 10.1007/s00262-020-02498-8 · DOI
  113. Roselli, 2013, Effects of Conventional Therapeutic Interventions on the Number and Function of Regulatory T Cells, Oncoimmunology, 2, e27025, 10.4161/onci.27025 · DOI
  114. Scurr, 2017, Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, Which Associate With Survival in Metastatic Colorectal Cancer, Clin Cancer Res, 23, 10.1158/1078-0432.CCR-17-0895 · DOI
  115. Shirahama, 2017, A Randomized Phase II Trial of Personalized Peptide Vaccine With Low Dose Cyclophosphamide in Biliary Tract Cancer, Cancer Sci, 108, 10.1111/cas.13193 · DOI
  116. Cheon, 2007, Diagnostic Utility of Interleukin-6 (IL-6) for Primary Bile Duct Cancer and Changes in Serum IL-6 Levels Following Photodynamic Therapy, Am J Gastroenterol, 102, 10.1111/j.1572-0241.2007.01403.x · DOI
  117. Hogdall, 2020, Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers, Clin Cancer Res, 26, 10.1158/1078-0432.CCR-19-2700 · DOI
  118. Yang, 2016, Potentiating the Antitumour Response of CD8(+) T Cells by Modulating Cholesterol Metabolism, Nature, 531, 10.1038/nature17412 · DOI · Paper page
  119. Pan, 2019, Potentiation of Kras Peptide Cancer Vaccine by Avasimibe, a Cholesterol Modulator, EBioMedicine, 49, 72, 10.1016/j.ebiom.2019.10.044 · DOI
  120. Xie, 2010, Naive Tumor-Specific CD4(+) T Cells Differentiated In Vivo Eradicate Established Melanoma, J Exp Med, 207, 10.1084/jem.20091921 · DOI
  121. Kumai, 2017, Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-Cell Responses, Cancer Immunol Res, 5, 72, 10.1158/2326-6066.CIR-16-0194 · DOI
  122. Croft, 2009, The Significance of OX40 and OX40L to T-Cell Biology and Immune Disease, Immunol Rev, 229, 10.1111/j.1600-065X.2009.00766.x · DOI
  123. 2015, FDA Approves First Oncolytic Virus Therapy: Imlygic for Melanoma, 36
  124. Atherton, 2018, Preclinical Development of Peptide Vaccination Combined With Oncolytic MG1-E6E7 for HPV-Associated Cancer, Vaccine, 36, 10.1016/j.vaccine.2018.02.070 · DOI
  125. Bezu, 2018, Trial Watch: Peptide-Based Vaccines in Anticancer Therapy, Oncoimmunology, 7, e1511506, 10.1080/2162402X.2018.1511506 · DOI

Cited by

Sorted by citations

See all 153

Metadata

Authors
Stephens, A. J., Burgess-Brown, N. A., & Jiang, S.
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2021-06-30
Volume
12
ISSN
1664-3224
DOI
10.3389/fimmu.2021.696791
Cited by
153
References
7
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
Innovate UK (104992, 133783)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review